What is Zacks Research’s Forecast for Alkermes Q1 Earnings?

Alkermes plc (NASDAQ:ALKS) – Research analysts at Zacks Research cut their Q1 2025 earnings estimates for shares of Alkermes in a note issued to investors on Wednesday, April 9th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.28 for the quarter, down from their prior estimate of $0.29. The consensus estimate for Alkermes’ current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Alkermes’ Q2 2025 earnings at $0.34 EPS, FY2025 earnings at $1.33 EPS, Q2 2026 earnings at $0.33 EPS, Q4 2026 earnings at $0.43 EPS, FY2026 earnings at $1.24 EPS and FY2027 earnings at $1.14 EPS.

A number of other research firms have also recently weighed in on ALKS. StockNews.com upgraded shares of Alkermes from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 13th. UBS Group upgraded shares of Alkermes from a “sell” rating to a “neutral” rating and upped their price target for the company from $21.00 to $38.00 in a report on Tuesday, March 4th. Royal Bank of Canada started coverage on shares of Alkermes in a research note on Thursday, March 13th. They issued a “sector perform” rating and a $40.00 price objective for the company. The Goldman Sachs Group upped their target price on Alkermes from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on Alkermes from $40.00 to $52.00 and gave the stock a “buy” rating in a research note on Thursday, March 27th. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Alkermes presently has an average rating of “Moderate Buy” and an average target price of $38.50.

Alkermes Stock Performance

NASDAQ:ALKS opened at $27.94 on Monday. The firm has a market capitalization of $4.61 billion, a PE ratio of 12.88, a PEG ratio of 2.20 and a beta of 0.39. The stock’s fifty day moving average is $33.00 and its 200 day moving average is $30.46. Alkermes has a fifty-two week low of $22.90 and a fifty-two week high of $36.45.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%.

Institutional Investors Weigh In On Alkermes

Several hedge funds have recently modified their holdings of the business. RTW Investments LP raised its stake in Alkermes by 13.6% in the fourth quarter. RTW Investments LP now owns 7,557,835 shares of the company’s stock worth $217,363,000 after buying an additional 903,802 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Alkermes by 1.1% in the 4th quarter. Renaissance Technologies LLC now owns 5,478,728 shares of the company’s stock valued at $157,568,000 after acquiring an additional 57,697 shares during the period. American Century Companies Inc. raised its position in shares of Alkermes by 6.5% in the 4th quarter. American Century Companies Inc. now owns 3,450,707 shares of the company’s stock worth $99,242,000 after acquiring an additional 209,740 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Alkermes by 4.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,019,508 shares of the company’s stock worth $86,842,000 after purchasing an additional 128,701 shares during the last quarter. Finally, Avoro Capital Advisors LLC bought a new stake in Alkermes during the fourth quarter valued at about $70,462,000. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Insiders Place Their Bets

In other Alkermes news, EVP Craig C. Hopkinson sold 144,419 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $35.53, for a total transaction of $5,131,207.07. Following the transaction, the executive vice president now directly owns 57,875 shares in the company, valued at $2,056,298.75. This represents a 71.39 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.89% of the stock is currently owned by company insiders.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.